Viking Therapeutics, Inc. (VKTX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Viking Therapeutics, Inc.
Address
9920 Pacific Heights Boulevard
San Diego, CA 92121
United States of America (the)
Phone
858 704 4660
Sector
Healthcare
Industry
Biotechnology
Employees
65
First IPO Date
April 28, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Brian Lian | President, Chief Executive Officer & Director | 1.05M | 1966 |
| Michael Morneau | Vice President of Finance & Administration | 375,333 | 1965 |
| Gregory S. Zante | Chief Financial Officer | 738,000 | 1971 |
| Marianne Mancini | Chief Operating Officer | 765,000 | 1965 |
| Neil Aubuchon | Chief Commercial Officer | 0 | 1970 |
| Katherine Mercier | Vice President of Quality and Compliance | 0 | N/A |
| Geoffrey E. Barker | Chief Development Officer | 0 | N/A |
| Hubert C. Chen | Chief Medical Officer | 0 | 1969 |
| Nils U. Olsson | Senior Vice President of Technical Operations | 0 | N/A |
| Kenneth Herman | Senior Vice President of Commercial, Marketing & Sales | 0 | N/A |
Description
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
